| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cholangiocarcinoma | 11 | 2017 | 495 | 2.280 |
Why?
|
| Bile Duct Neoplasms | 9 | 2017 | 495 | 1.980 |
Why?
|
| Bile Ducts, Intrahepatic | 7 | 2011 | 336 | 1.420 |
Why?
|
| Carcinoma, Hepatocellular | 7 | 2023 | 2027 | 0.740 |
Why?
|
| Liver Neoplasms | 10 | 2023 | 4562 | 0.720 |
Why?
|
| Proto-Oncogene Proteins c-kit | 2 | 2017 | 481 | 0.630 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2017 | 511 | 0.540 |
Why?
|
| Liver | 4 | 2016 | 2901 | 0.480 |
Why?
|
| Benzenesulfonates | 2 | 2011 | 195 | 0.420 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2009 | 60 | 0.350 |
Why?
|
| Kyphosis | 1 | 2008 | 43 | 0.320 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2013 | 1268 | 0.300 |
Why?
|
| Oncolytic Virotherapy | 2 | 2007 | 253 | 0.300 |
Why?
|
| Measles virus | 1 | 2006 | 14 | 0.290 |
Why?
|
| Hepatitis C | 3 | 2017 | 524 | 0.280 |
Why?
|
| Pyridines | 2 | 2011 | 1245 | 0.280 |
Why?
|
| Osteoporosis | 1 | 2008 | 231 | 0.270 |
Why?
|
| Parvovirus | 1 | 2004 | 7 | 0.250 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 2 | 2017 | 184 | 0.250 |
Why?
|
| STAT3 Transcription Factor | 2 | 2016 | 1122 | 0.240 |
Why?
|
| Neoplasm Staging | 5 | 2020 | 13673 | 0.240 |
Why?
|
| Hepacivirus | 2 | 2016 | 398 | 0.220 |
Why?
|
| Liver Cirrhosis | 4 | 2023 | 944 | 0.200 |
Why?
|
| Antiviral Agents | 3 | 2019 | 1234 | 0.200 |
Why?
|
| Positron-Emission Tomography | 1 | 2010 | 2182 | 0.200 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2011 | 4769 | 0.190 |
Why?
|
| Sofosbuvir | 1 | 2019 | 22 | 0.170 |
Why?
|
| Genetic Vectors | 1 | 2004 | 1684 | 0.170 |
Why?
|
| Colitis | 2 | 2020 | 340 | 0.160 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2020 | 191 | 0.160 |
Why?
|
| Humans | 32 | 2023 | 262295 | 0.150 |
Why?
|
| Genetic Therapy | 2 | 2007 | 1608 | 0.150 |
Why?
|
| Signal Transduction | 4 | 2016 | 11970 | 0.150 |
Why?
|
| Liver Diseases, Parasitic | 1 | 2017 | 4 | 0.150 |
Why?
|
| Caroli Disease | 1 | 2017 | 5 | 0.150 |
Why?
|
| Choledochal Cyst | 1 | 2017 | 13 | 0.150 |
Why?
|
| Transforming Growth Factor beta2 | 1 | 2016 | 32 | 0.150 |
Why?
|
| Fanconi Anemia Complementation Group D2 Protein | 1 | 2016 | 41 | 0.140 |
Why?
|
| Klatskin Tumor | 1 | 2017 | 29 | 0.140 |
Why?
|
| Asia | 1 | 2017 | 142 | 0.140 |
Why?
|
| Pregnancy, Animal | 1 | 2016 | 92 | 0.140 |
Why?
|
| Stem Cell Factor | 1 | 2016 | 89 | 0.140 |
Why?
|
| Liver Transplantation | 2 | 2017 | 1105 | 0.140 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2017 | 77 | 0.140 |
Why?
|
| Hepatitis C, Chronic | 2 | 2019 | 451 | 0.140 |
Why?
|
| Smad2 Protein | 1 | 2016 | 88 | 0.140 |
Why?
|
| Spectrin | 1 | 2016 | 85 | 0.140 |
Why?
|
| Rats, Inbred F344 | 3 | 2010 | 226 | 0.130 |
Why?
|
| ELAV-Like Protein 1 | 1 | 2015 | 18 | 0.130 |
Why?
|
| Colonoscopy | 2 | 2018 | 518 | 0.130 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2016 | 293 | 0.120 |
Why?
|
| Immunologic Factors | 1 | 2018 | 656 | 0.120 |
Why?
|
| Natural Language Processing | 1 | 2015 | 120 | 0.120 |
Why?
|
| Hepatitis B | 1 | 2017 | 259 | 0.120 |
Why?
|
| fas Receptor | 1 | 2015 | 185 | 0.120 |
Why?
|
| Genomic Instability | 1 | 2016 | 519 | 0.120 |
Why?
|
| Documentation | 1 | 2015 | 206 | 0.110 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2017 | 421 | 0.110 |
Why?
|
| Early Detection of Cancer | 2 | 2017 | 1267 | 0.100 |
Why?
|
| Veterans | 1 | 2023 | 1654 | 0.100 |
Why?
|
| Quality Indicators, Health Care | 1 | 2015 | 350 | 0.100 |
Why?
|
| Fatal Outcome | 2 | 2017 | 826 | 0.100 |
Why?
|
| Niacinamide | 2 | 2011 | 421 | 0.100 |
Why?
|
| Hepatic Stellate Cells | 1 | 2011 | 29 | 0.100 |
Why?
|
| Neoplasms | 5 | 2019 | 15198 | 0.100 |
Why?
|
| Prognosis | 5 | 2017 | 21745 | 0.100 |
Why?
|
| Biomarkers, Tumor | 2 | 2017 | 10348 | 0.090 |
Why?
|
| Paracrine Communication | 1 | 2011 | 129 | 0.090 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2020 | 1251 | 0.090 |
Why?
|
| Hepatectomy | 1 | 2017 | 1009 | 0.090 |
Why?
|
| Promoter Regions, Genetic | 1 | 2017 | 3077 | 0.090 |
Why?
|
| Adenoma | 1 | 2015 | 718 | 0.090 |
Why?
|
| Phenylurea Compounds | 2 | 2011 | 581 | 0.090 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2010 | 205 | 0.090 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2010 | 366 | 0.090 |
Why?
|
| Rats | 4 | 2011 | 6107 | 0.080 |
Why?
|
| Injections, Intravenous | 2 | 2007 | 576 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2017 | 3264 | 0.080 |
Why?
|
| Tyrosine | 1 | 2009 | 500 | 0.080 |
Why?
|
| Diabetes Mellitus | 1 | 2017 | 1066 | 0.080 |
Why?
|
| Male | 14 | 2020 | 123333 | 0.080 |
Why?
|
| Chemoradiotherapy | 1 | 2017 | 1947 | 0.080 |
Why?
|
| Cell Line, Tumor | 6 | 2016 | 14559 | 0.080 |
Why?
|
| Cholesterol, HDL | 1 | 2009 | 341 | 0.080 |
Why?
|
| Morbillivirus | 1 | 2007 | 1 | 0.070 |
Why?
|
| Survival Rate | 4 | 2017 | 12240 | 0.070 |
Why?
|
| Cytopathogenic Effect, Viral | 1 | 2006 | 38 | 0.070 |
Why?
|
| Membrane Cofactor Protein | 1 | 2006 | 10 | 0.070 |
Why?
|
| Measles Vaccine | 1 | 2006 | 10 | 0.070 |
Why?
|
| Colonic Neoplasms | 1 | 2015 | 1389 | 0.070 |
Why?
|
| Measles | 1 | 2007 | 35 | 0.070 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2013 | 2485 | 0.070 |
Why?
|
| Animals | 9 | 2016 | 59517 | 0.070 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2006 | 223 | 0.070 |
Why?
|
| Virus Internalization | 1 | 2007 | 88 | 0.070 |
Why?
|
| Enzyme Activation | 1 | 2009 | 1760 | 0.070 |
Why?
|
| Symporters | 1 | 2006 | 98 | 0.070 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2008 | 275 | 0.070 |
Why?
|
| Pyrroles | 1 | 2010 | 584 | 0.070 |
Why?
|
| Hematologic Neoplasms | 1 | 2017 | 1900 | 0.070 |
Why?
|
| Apoptosis | 2 | 2010 | 7604 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 1 | 2018 | 4386 | 0.060 |
Why?
|
| Endothelial Cells | 1 | 2011 | 1046 | 0.060 |
Why?
|
| Genetic Engineering | 1 | 2006 | 287 | 0.060 |
Why?
|
| Iodine Radioisotopes | 1 | 2006 | 373 | 0.060 |
Why?
|
| Respiratory Insufficiency | 1 | 2008 | 332 | 0.060 |
Why?
|
| Transgenes | 1 | 2007 | 557 | 0.060 |
Why?
|
| Oncolytic Viruses | 1 | 2007 | 183 | 0.060 |
Why?
|
| Neoplastic Stem Cells | 1 | 2013 | 1439 | 0.060 |
Why?
|
| Suppression, Genetic | 1 | 2004 | 67 | 0.060 |
Why?
|
| Genes, Transgenic, Suicide | 1 | 2004 | 69 | 0.060 |
Why?
|
| Obesity | 1 | 2017 | 2892 | 0.060 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2011 | 1759 | 0.060 |
Why?
|
| Ultrasonography | 1 | 2010 | 1870 | 0.060 |
Why?
|
| Genome, Viral | 1 | 2004 | 155 | 0.060 |
Why?
|
| Neoadjuvant Therapy | 1 | 2017 | 4980 | 0.060 |
Why?
|
| Radiography | 1 | 2008 | 1914 | 0.060 |
Why?
|
| Cytokines | 1 | 2013 | 2823 | 0.060 |
Why?
|
| Dependovirus | 1 | 2004 | 136 | 0.060 |
Why?
|
| Neoplasm Transplantation | 1 | 2006 | 1517 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 2 | 2010 | 5379 | 0.060 |
Why?
|
| Skin Neoplasms | 1 | 2020 | 4656 | 0.060 |
Why?
|
| Aged | 7 | 2023 | 70372 | 0.060 |
Why?
|
| Female | 12 | 2020 | 142294 | 0.060 |
Why?
|
| Gene Targeting | 1 | 2004 | 293 | 0.060 |
Why?
|
| Vaccines, Synthetic | 1 | 2004 | 356 | 0.050 |
Why?
|
| Organ Specificity | 1 | 2004 | 696 | 0.050 |
Why?
|
| Melanoma | 1 | 2020 | 5320 | 0.050 |
Why?
|
| Risk Factors | 2 | 2017 | 17611 | 0.050 |
Why?
|
| Viral Proteins | 1 | 2004 | 437 | 0.050 |
Why?
|
| Phosphorylation | 1 | 2009 | 4809 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2007 | 3817 | 0.050 |
Why?
|
| Virus Replication | 1 | 2004 | 706 | 0.050 |
Why?
|
| Deprescriptions | 1 | 2020 | 24 | 0.050 |
Why?
|
| Jaundice | 1 | 2020 | 39 | 0.040 |
Why?
|
| Aspartate Aminotransferases | 1 | 2020 | 153 | 0.040 |
Why?
|
| Simeprevir | 1 | 2019 | 9 | 0.040 |
Why?
|
| Fluorenes | 1 | 2019 | 17 | 0.040 |
Why?
|
| Alanine Transaminase | 1 | 2020 | 226 | 0.040 |
Why?
|
| Ascites | 1 | 2020 | 198 | 0.040 |
Why?
|
| Mice | 5 | 2016 | 34409 | 0.040 |
Why?
|
| Sustained Virologic Response | 1 | 2019 | 57 | 0.040 |
Why?
|
| Carbamates | 1 | 2019 | 77 | 0.040 |
Why?
|
| Cancer Vaccines | 1 | 2004 | 699 | 0.040 |
Why?
|
| Pyrrolidines | 1 | 2019 | 113 | 0.040 |
Why?
|
| Valine | 1 | 2019 | 176 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2008 | 7218 | 0.040 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2004 | 1238 | 0.040 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2019 | 121 | 0.040 |
Why?
|
| Ribavirin | 1 | 2019 | 178 | 0.040 |
Why?
|
| Incidence | 1 | 2008 | 5712 | 0.040 |
Why?
|
| Interferons | 1 | 2019 | 290 | 0.040 |
Why?
|
| Antineoplastic Agents | 2 | 2011 | 14302 | 0.040 |
Why?
|
| Abdominal Pain | 1 | 2020 | 369 | 0.040 |
Why?
|
| Fetal Alcohol Spectrum Disorders | 1 | 2016 | 15 | 0.040 |
Why?
|
| Alemtuzumab | 1 | 2017 | 198 | 0.040 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2004 | 1247 | 0.040 |
Why?
|
| Fever | 1 | 2020 | 498 | 0.040 |
Why?
|
| Palliative Care | 1 | 2008 | 2032 | 0.040 |
Why?
|
| Retrospective Studies | 4 | 2023 | 38030 | 0.040 |
Why?
|
| Tertiary Healthcare | 1 | 2016 | 44 | 0.040 |
Why?
|
| Alcohol Drinking | 1 | 2020 | 553 | 0.040 |
Why?
|
| Lipid Peroxidation | 1 | 2016 | 154 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2020 | 548 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2023 | 855 | 0.030 |
Why?
|
| Hep G2 Cells | 1 | 2016 | 155 | 0.030 |
Why?
|
| Middle Aged | 6 | 2020 | 86512 | 0.030 |
Why?
|
| CTLA-4 Antigen | 1 | 2020 | 658 | 0.030 |
Why?
|
| Multiple Organ Failure | 1 | 2017 | 178 | 0.030 |
Why?
|
| Benzimidazoles | 1 | 2019 | 428 | 0.030 |
Why?
|
| Cardiovascular Diseases | 1 | 2009 | 2206 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 2 | 2016 | 3985 | 0.030 |
Why?
|
| Models, Biological | 1 | 2004 | 3243 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 2019 | 621 | 0.030 |
Why?
|
| Ethanol | 1 | 2016 | 265 | 0.030 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2016 | 278 | 0.030 |
Why?
|
| Fas Ligand Protein | 1 | 2015 | 152 | 0.030 |
Why?
|
| Diarrhea | 1 | 2018 | 689 | 0.030 |
Why?
|
| Colon | 1 | 2018 | 673 | 0.030 |
Why?
|
| Disease Progression | 2 | 2016 | 6697 | 0.030 |
Why?
|
| Ipilimumab | 1 | 2018 | 719 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2016 | 7554 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2020 | 1054 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 2324 | 0.030 |
Why?
|
| Imidazoles | 1 | 2019 | 1004 | 0.030 |
Why?
|
| Consensus | 1 | 2017 | 1004 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 1221 | 0.030 |
Why?
|
| Coinfection | 1 | 2015 | 189 | 0.030 |
Why?
|
| B7-H1 Antigen | 1 | 2020 | 1024 | 0.030 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2019 | 1041 | 0.030 |
Why?
|
| Animals, Newborn | 1 | 2016 | 1329 | 0.030 |
Why?
|
| Cell Death | 1 | 2015 | 672 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2016 | 2310 | 0.030 |
Why?
|
| Queensland | 1 | 2011 | 4 | 0.030 |
Why?
|
| Belgium | 1 | 2011 | 47 | 0.030 |
Why?
|
| Laser Capture Microdissection | 1 | 2011 | 42 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2017 | 6896 | 0.030 |
Why?
|
| Killer Cells, Natural | 1 | 2017 | 907 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2015 | 1077 | 0.030 |
Why?
|
| RNA Interference | 1 | 2016 | 1411 | 0.030 |
Why?
|
| Recurrence | 1 | 2020 | 4785 | 0.020 |
Why?
|
| Cell Proliferation | 2 | 2016 | 7238 | 0.020 |
Why?
|
| United States | 2 | 2023 | 15564 | 0.020 |
Why?
|
| Protein Biosynthesis | 1 | 2015 | 888 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2017 | 3023 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2017 | 1417 | 0.020 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2016 | 973 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2016 | 2215 | 0.020 |
Why?
|
| Transfection | 1 | 2015 | 2936 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 4979 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 4348 | 0.020 |
Why?
|
| Trastuzumab | 1 | 2011 | 697 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2011 | 1054 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 4129 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 1329 | 0.020 |
Why?
|
| DNA Repair | 1 | 2016 | 1871 | 0.020 |
Why?
|
| DNA Damage | 1 | 2016 | 1950 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2008 | 30002 | 0.020 |
Why?
|
| Cell Survival | 1 | 2015 | 3043 | 0.020 |
Why?
|
| Cell Movement | 1 | 2016 | 2463 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2016 | 3128 | 0.020 |
Why?
|
| Mitochondrial Proteins | 1 | 2010 | 373 | 0.020 |
Why?
|
| ras Proteins | 1 | 2011 | 771 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2010 | 622 | 0.020 |
Why?
|
| Multiple Myeloma | 1 | 2019 | 2152 | 0.020 |
Why?
|
| Hypolipidemic Agents | 1 | 2009 | 190 | 0.020 |
Why?
|
| Biopsy | 1 | 2015 | 3452 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2011 | 876 | 0.020 |
Why?
|
| Quinazolines | 1 | 2011 | 924 | 0.020 |
Why?
|
| Genotype | 1 | 2015 | 4108 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2011 | 3529 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2011 | 2504 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2009 | 1550 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2011 | 1338 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2015 | 6134 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2017 | 33021 | 0.020 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2011 | 1284 | 0.020 |
Why?
|
| Indoles | 1 | 2010 | 1011 | 0.010 |
Why?
|
| Precision Medicine | 1 | 2011 | 1160 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2015 | 6931 | 0.010 |
Why?
|
| Patient Selection | 1 | 2011 | 2061 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2019 | 12927 | 0.010 |
Why?
|
| Pregnancy | 1 | 2016 | 7552 | 0.010 |
Why?
|
| Head and Neck Neoplasms | 1 | 2019 | 3977 | 0.010 |
Why?
|
| ErbB Receptors | 1 | 2011 | 2297 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2011 | 5010 | 0.010 |
Why?
|
| Mitochondria | 1 | 2010 | 1282 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2011 | 5601 | 0.010 |
Why?
|
| Mice, SCID | 1 | 2007 | 1871 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 7580 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 6223 | 0.010 |
Why?
|
| Adult | 2 | 2018 | 78140 | 0.010 |
Why?
|
| Molecular Targeted Therapy | 1 | 2011 | 2334 | 0.010 |
Why?
|
| Tumor Microenvironment | 1 | 2011 | 2860 | 0.010 |
Why?
|
| Phenotype | 1 | 2011 | 6260 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 8880 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 2007 | 1317 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2011 | 5156 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2009 | 3757 | 0.010 |
Why?
|
| Gene Expression | 1 | 2007 | 3566 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2011 | 5539 | 0.010 |
Why?
|
| Time Factors | 1 | 2011 | 12983 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2019 | 15708 | 0.010 |
Why?
|
| Mutation | 1 | 2011 | 15179 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 2007 | 4660 | 0.010 |
Why?
|